Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
R42 Group operates as both an investor and incubator, backing and inventing deep science startups with a strong emphasis on AI-driven biotech and longevity technologies at predominantly preclinical and early development stages. Some portfolio initiatives have reached commercialization or exit (e.g., speech and handwriting recognition platforms acquired by Apple, Motorola; biotech asset sold to Seed Health for menopause).
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on R42 Group.